MedTrace Logo

Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo

NCT07499739 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-05-19

No results posted yet for this study

Summary

The study Mbote-TRAXX evaluates humoral and cellular immune responses in individuals vaccinated against mpox with the MVA-BN or LC16m8 vaccine administered as part of a routine mpox vaccination campaign in Kinshasa, Democratic Republic of the Congo (DRC). Participants will be followed up at multiple time points after vaccination in order to assess the kinetics and durability of the immune response by collection of blood samples. It is planned to include approximately 150 participants vaccinated with MVA-BN and 150 participants vaccinated with LC16m8.

Conditions

Interventions

PROCEDURE

blood sample collection

10 mL of blood will be collected at every visit and additional 20 mL blood samples will be taken from a subgroup of participants at every visit.

Sponsors & Collaborators

  • Institut National de Recherche Biomédicale (INRB). Kinshasa, Democratic Republic of Congo

    collaborator UNKNOWN

  • Programme Elargi de Vaccination de République Démocratique du Congo

    collaborator UNKNOWN

  • National Institute of Public Health of the Democratic Republic of the Congo

    collaborator UNKNOWN

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2026-12-15
Completion
2028-12-15

Countries

  • Democratic Republic of the Congo

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07499739 on ClinicalTrials.gov